The council, made up of seasoned pharma execs, will function as consultants to rbb's health clients and health team.
Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.
AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practiceMarch 21, 2018
The potential is real, but companies and technology gurus often speak of machine learning as a catch-all solution. The hype may be slowing AI's incremental growth in healthcare, experts say.
MM&M has announced its annual showcase of executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.
Want to get an ethicist agitated? Mention the integration of voice-activation and other tech into healthcare. Experts say navigating this area is a work in progress.
Recently, Forbes ran an article from Wild Pixel Media founder and CEO Carlos Machicao lamenting the fact that healthcare advertising is boring.
Pharma has backed a number of AR-based games for physician learning and marketing. They're meant to complement live learning, but mobile games may do a better job teaching certain skills.
The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
Purdue's decision to pull OxyContin sales reps highlights what has been the biggest part of marketing budgets. Did we just see the tipping point?
The company is also looking to better combine its web and social media presence.
Amazon moves into medical supply market; Big Pharma gets a tax cut; Former Celgene CEO plans Senate run.
There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.
At a time when value-based healthcare is a more common objective among stakeholders, EHR data can enable collaboration among payers, providers, health systems, and pharma manufacturers.
PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.
We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma marketing. Here's what they had to say.
In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.
Spark has priced its cure for a rare form of blindness at $425,000 per eye. But rather than the science or the cost, pharma is buzzing over the company's outcomes-based pricing model
Glaze worked in Edelman's market access practice for more than seven years.
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
It was at an MM&M event back in late 2013 that I got my first glimpse of how this industry feels about big data.
Alan Maine has joined Edelman as a senior director in its London health team.
Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market
How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
VP of investor relations Teri Loxam will take over Ambrose's role in January.